Russell Hogg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Russell Hogg has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Michael Friedlander
Gynaecological Cancer Centre, Royal Hospital for Women, Sydney, Australia
2 shared publicationsJames Scurry
Gynaecological Cancer Centre, Royal Hospital for Women, Sydney, Australia
1 shared publicationNeville Hacker
Gynaecological Cancer Centre, Royal Hospital for Women, Sydney, Australia
1 shared publicationSoo-Nyung Kim
Gynaecological Cancer Centre, Royal Hospital for Women, Sydney, Australia
1 shared publication
Latest Publications
- 1 July 2007
- Published by Elsevier in Gynecologic Oncology
- Vol. 106 (1) , 44-51
Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma
- 1 July 2007
- Published by Elsevier in Gynecologic Oncology
- Vol. 106 (1) , 44-51
Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma
- 1 April 2003
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 3 (2) , 234-240
Role of systemic chemotherapy in metastatic cervical cancer
Cervical cancer is a chemoresponsive tumor. Concurrent chemotherapy with cisplatin and radiotherapy has resulted in improved survival in patients with locally advanced cervical cancer and is now standard of care. There are many active drugs in metastatic cervical cancer with cisplatin being the most active single agent. Although response rates are significantly higher with cisplatin combinations, to date, there is no evidence to suggest this is associated with an improved survival. However, this is still an area that is attracting much research interest. The role of chemotherapy in metastatic cervical cancer will be reviewed together with some of the new areas of research.
- 1 April 2003
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 3 (2) , 234-240
Role of systemic chemotherapy in metastatic cervical cancer
Cervical cancer is a chemoresponsive tumor. Concurrent chemotherapy with cisplatin and radiotherapy has resulted in improved survival in patients with locally advanced cervical cancer and is now standard of care. There are many active drugs in metastatic cervical cancer with cisplatin being the most active single agent. Although response rates are significantly higher with cisplatin combinations, to date, there is no evidence to suggest this is associated with an improved survival. However, this is still an area that is attracting much research interest. The role of chemotherapy in metastatic cervical cancer will be reviewed together with some of the new areas of research.